JP6087367B2 - 三環式化合物、それらを含む組成物およびそれらの使用 - Google Patents

三環式化合物、それらを含む組成物およびそれらの使用 Download PDF

Info

Publication number
JP6087367B2
JP6087367B2 JP2014540635A JP2014540635A JP6087367B2 JP 6087367 B2 JP6087367 B2 JP 6087367B2 JP 2014540635 A JP2014540635 A JP 2014540635A JP 2014540635 A JP2014540635 A JP 2014540635A JP 6087367 B2 JP6087367 B2 JP 6087367B2
Authority
JP
Japan
Prior art keywords
branched
linear
compound according
alkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014540635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533264A (ja
Inventor
ベン‐サッソン，シュミュエル
デーガン，アリー
，シャロン パールズ
，シャロン パールズ
Original Assignee
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド, イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド filed Critical イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド
Publication of JP2014533264A publication Critical patent/JP2014533264A/ja
Application granted granted Critical
Publication of JP6087367B2 publication Critical patent/JP6087367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014540635A 2011-11-15 2012-11-15 三環式化合物、それらを含む組成物およびそれらの使用 Active JP6087367B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161559964P 2011-11-15 2011-11-15
US61/559,964 2011-11-15
US201261603508P 2012-02-27 2012-02-27
US61/603,508 2012-02-27
PCT/IL2012/050461 WO2013072915A1 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Publications (2)

Publication Number Publication Date
JP2014533264A JP2014533264A (ja) 2014-12-11
JP6087367B2 true JP6087367B2 (ja) 2017-03-01

Family

ID=48429067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540635A Active JP6087367B2 (ja) 2011-11-15 2012-11-15 三環式化合物、それらを含む組成物およびそれらの使用

Country Status (25)

Country Link
US (1) US9447040B2 (enExample)
EP (1) EP2802320B1 (enExample)
JP (1) JP6087367B2 (enExample)
KR (1) KR101986272B1 (enExample)
CN (1) CN104010636B (enExample)
AU (1) AU2012338362B2 (enExample)
BR (1) BR112014011641B1 (enExample)
CA (1) CA2855759C (enExample)
CL (1) CL2014001278A1 (enExample)
CO (1) CO7020909A2 (enExample)
DK (1) DK2802320T3 (enExample)
ES (1) ES2729713T3 (enExample)
HR (1) HRP20190927T1 (enExample)
HU (1) HUE043827T2 (enExample)
IN (1) IN2014CN03610A (enExample)
MX (1) MX347570B (enExample)
PE (1) PE20141940A1 (enExample)
PH (1) PH12014501061B1 (enExample)
PL (1) PL2802320T3 (enExample)
PT (1) PT2802320T (enExample)
RU (1) RU2624446C9 (enExample)
SG (1) SG11201402258UA (enExample)
SI (1) SI2802320T1 (enExample)
WO (1) WO2013072915A1 (enExample)
ZA (1) ZA201404065B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
ES2924728T3 (es) 2015-06-15 2022-10-10 Raziel Therapeutics Ltd Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
AU2020347539A1 (en) * 2019-09-15 2022-03-31 Raziel Therapeutics Ltd. Compositions for the treatment of solid tumors
IL295014B1 (en) * 2020-01-28 2026-05-01 Raziel Therapeutics Ltd A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma
US20240041827A1 (en) * 2020-09-16 2024-02-08 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
IL301325A (en) * 2020-09-16 2023-05-01 Raziel Therapeutics Ltd Compositions and methods for the treatment of lipid-related disorders
AU2022270984A1 (en) * 2021-05-06 2023-11-23 Raziel Therapeutics Ltd. Crystalline carbazole derivative
IL310051A (en) * 2021-07-28 2024-03-01 Raziel Therapeutics Ltd Compositions and methods for treating lipoma pain
CN115073374B (zh) * 2022-06-14 2023-10-27 五邑大学 一种α-葡萄糖苷酶抑制剂及其制备方法和应用
AU2023378681A1 (en) * 2022-11-07 2025-05-15 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
GB832568A (en) * 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
FR1186832A (fr) * 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
GB866418A (en) * 1958-01-25 1961-04-26 Bayer Ag Phenoxazine derivatives
US3836587A (en) * 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AR205331A1 (es) * 1972-07-24 1976-04-30 Hoffmann La Roche Procedimiento para la preparacion de carbazoles
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU5644396A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry
US6440961B1 (en) * 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
US6933313B2 (en) * 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
WO2003027084A1 (en) * 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
US7428091B2 (en) * 2004-11-15 2008-09-23 Gentex Corporation Electrochromic compounds and associated media and devices
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US20090317372A1 (en) 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) * 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2011274787B2 (en) * 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Also Published As

Publication number Publication date
RU2624446C9 (ru) 2018-04-04
HRP20190927T1 (hr) 2019-08-23
DK2802320T3 (da) 2019-05-27
PE20141940A1 (es) 2014-12-18
CO7020909A2 (es) 2014-08-11
US9447040B2 (en) 2016-09-20
AU2012338362B2 (en) 2017-05-18
PH12014501061B1 (en) 2018-12-12
CL2014001278A1 (es) 2014-12-26
SG11201402258UA (en) 2014-06-27
EP2802320B1 (en) 2019-02-20
JP2014533264A (ja) 2014-12-11
RU2014119711A (ru) 2015-12-27
MX2014005765A (es) 2015-09-23
KR20140099492A (ko) 2014-08-12
PL2802320T3 (pl) 2019-09-30
HUE043827T2 (hu) 2019-09-30
BR112014011641A2 (pt) 2017-05-02
IN2014CN03610A (enExample) 2015-10-09
EP2802320A4 (en) 2015-08-12
BR112014011641B1 (pt) 2020-10-27
EP2802320A1 (en) 2014-11-19
WO2013072915A1 (en) 2013-05-23
CA2855759A1 (en) 2013-05-23
US20140329877A1 (en) 2014-11-06
KR101986272B1 (ko) 2019-06-05
CA2855759C (en) 2020-03-10
SI2802320T1 (sl) 2019-08-30
CN104010636B (zh) 2017-04-12
ES2729713T3 (es) 2019-11-05
ZA201404065B (en) 2015-11-25
PH12014501061A1 (en) 2014-06-23
MX347570B (es) 2017-05-02
RU2624446C2 (ru) 2017-07-04
PT2802320T (pt) 2019-06-17
CN104010636A (zh) 2014-08-27
AU2012338362A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CN104010636B (zh) 三环化合物、包含它们的组合物及其用途
JP5596680B2 (ja) 経口抗がん製剤
WO2017167180A1 (zh) 沃替西汀的帕莫酸盐及其晶型
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
JP2016512526A (ja) オナプリストン多形体及び使用方法
WO2016020919A1 (en) Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
CN106187942A (zh) 苯并噻唑酮化合物
CN114945570A (zh) 雌激素受体调节剂的盐和形式
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
BR112012013325B1 (pt) Composição farmacêutica e uso
WO2023213182A1 (zh) 一种卡瑞斯汀的盐及其用途
JP2021533080A (ja) 結晶トラニラスト塩およびこれらの医薬的な使用
JP2016539994A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
CN104557944B (zh) 一种降糖药物及其制备方法
BR112016009918B1 (pt) Composto apresentando maior inibição da atividade da proteína quinase g, seu uso e seu método de preparação, e composição farmacêutica
CN103483282B (zh) 苯基取代的三唑酰胺类化合物及用途
CN103467398B (zh) 三唑酰胺类化合物、其制备方法和其抗糖尿病用途
JP2024539335A (ja) 新規抗うつ剤、及び神経可塑剤とその治療的使用
CN120698929A (zh) 一种联苯烯烃类化合物及其药物组合物和应用
CN103467399B (zh) 三唑酰胺类化合物、其制备方法和其用途
CN104736525A (zh) 作为β-2肾上腺受体激动剂的苯并噻唑酮化合物的盐
CN101242836A (zh) 改善觉醒状态的方法
JP2013107856A (ja) アデノシン誘導体を含有する炎症性眼疾患の治療又は予防剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170201

R150 Certificate of patent or registration of utility model

Ref document number: 6087367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250